NMN: Why Is It Banned in France, and Where Does Regulation Stand?

NMN is not authorized as a dietary supplement in France or in the European Union. It falls under novel food status, due to lack of significant consumption history in the Union before May 15, 1997, which requires prior authorization before any market release. As long as this authorization has not been granted by the European Commission, NMN cannot be legally marketed, which explains its disappearance from European shelves.

A novel food is a food or ingredient that was not consumed significantly in the European Union before May 15, 1997. Regulation (EU) 2015/2283 requires prior authorization before any commercialization, following scientific safety evaluation by the EFSA and then a decision by the European Commission. Without authorization, the ingredient cannot be sold either as a food or as a supplement.

Because national authorities began enforcing the novel food classification. NMN was sold through parallel channels until regulatory enforcement caught up with the market: brands withdrew their stocks and the ingredient disappeared from conventional European commerce. This was neither a health alert nor a price problem, but the enforcement of a 2015 regulation.

Yes, this is the principle of the novel food regulation: authorization is European and applies to all Member States, with the same usage conditions. This avoids the national differences that existed before harmonization. Market surveillance, however, remains the responsibility of each Member State's authorities, which explains why effective enforcement can vary over time from one country to another.

The United Kingdom applies a comparable framework in principle, with its own authority responsible for reviewing applications. The approaches are aligned in substance, but timelines and procedures differ, so an ingredient can be authorized on one side and not the other. A British website selling a product therefore tells us nothing about its status in the European Union.

In May 2026, the EFSA published a favorable safety opinion on synthetic β-NMN, following an application submitted by a manufacturer. The opinion concludes that an intake of up to 300 mg per day is safe for adults, excluding pregnant and nursing women, and evaluates NMN as a source of niacin, i.e., vitamin B3. This is an important step, but an EFSA opinion is not an authorization.

No, not yet. The opinion concerns safety: it is the prerequisite scientific step. Authorization is a matter of decision by the European Commission, which must be published in the Official Journal and list the ingredient on the Union list with its conditions of use. Until this publication has taken place, NMN remains technically unauthorized in the Union.

It will be listed on the Union list with precise conditions of use: target population, maximum daily dose, and food categories. One technical point matters: authorizations may come with a data protection period benefiting the applicant, during which other manufacturers cannot rely on their dossier. An authorization therefore does not necessarily mean that all NMN products on the market become legal.

It is a mechanism provided for in the regulations: the company that funded the studies and submitted the dossier can benefit from an exclusivity period during which its data cannot be used by competitors, who must then submit their own dossier. This explains why an ingredient can be authorized on paper while remaining, in practice, reserved to one or a few suppliers for several years.

Because it completed the procedure earlier. Nicotinamide riboside chloride was authorized by Implementing Regulation (EU) 2020/16 of January 10, 2020, as a source of niacin in supplements intended for the adult population. Both molecules are NAD precursors evaluated as sources of vitamin B3, but only one has authorization. The difference is not biological, it is administrative.

The authorization sets precise conditions that form an integral part of it: use limited to 300 mg per day for the general adult population, and to 230 mg per day for pregnant and nursing women. Its use was subsequently extended to other food categories, particularly meal replacements and foods for special medical purposes. These conditions are listed in the Union list.

NAD is a coenzyme present in all cells, involved in many energy metabolism reactions. NMN is one of its precursors, as is nicotinamide riboside or niacin. Public interest stems from the field of longevity. However, it is important to distinguish the scientific interest in a subject from the claims a brand is entitled to make: in Europe, only authorized claims can be used.

Niacin has several authorized claims: contributing to normal energy metabolism, normal functioning of the nervous system, normal psychological functions, maintenance of normal mucous membranes and skin, and reduction of fatigue. These are the only legally usable formulations. No anti-aging or longevity claims are authorized, for vitamin B3 as for any other nutrient.

No. No claim relating to slowing aging, extending lifespan, or longevity is authorized in the European Union. A brand using this vocabulary falls outside the legal framework, regardless of the ingredient. This is a useful signal: the vocabulary used by a seller often reveals more about its credibility than its ingredient list.

It is available, but the purchase is made outside the European legal framework. NMN is still sold in certain countries outside the Union, and products sometimes circulate under disguised designations, including as laboratory chemicals. Consequence: no guarantee regarding purity, actual composition, or absence of contaminants, and no health claims can legally be made.

That is not what the regulations say. Lack of authorization does not mean an ingredient is dangerous: it means the evaluation procedure is not complete. In the case of NMN, the opinion issued by the EFSA in May 2026 is even favorable in terms of safety, up to 300 mg per day in adults outside pregnancy and breastfeeding. The real risk today is not the molecule but the uncontrolled quality of products purchased outside the framework.

Buying outside the European framework exposes you to products whose purity and composition are not controlled, with no recourse in case of problems, and without any claims being guaranteed. Waiting for authorization means eventually having a product whose dose, target population, and specifications will have been evaluated. For daily and prolonged use, the second option is far more reasonable.

First, note the exact name of the molecule on the label, not just the brand name. Then consult the catalog of novel foods published by the European Commission. If the ingredient is authorized, check its conditions of use in the Union list: population, maximum dose, product categories. If in doubt, your pharmacist can help you read a label.

Yes, the same mechanism has caught up with several ingredients that have become popular, including spermidine in concentrated extract form, certain quercetin formulations, and monk fruit. The rule is always the same: without documented significant consumption in the Union before 1997, the ingredient falls under novel food status and must obtain authorization. Popularity on social media changes nothing about its status.